Dose to Pelvic Bone Marrow Defined with FDG-PET Predicts for Hematologic Nadirs in Anal Cancer Patients Treated with Concurrent Chemo-radiation

Pierfrancesco Franco, Francesca Arcadipane, Riccardo Ragona, Adriana Lesca, Elena Gallio, Massimiliano Mistrangelo, Elisabetta Trino, Paola Cassoni, Vincenzo Arena, Massimo Baccega, Patrizia Racca, Riccardo Faletti, Nadia Rondi, Mario Morino, Umberto Ricardi

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To investigate whether irradiated volume of pelvic active bone marrow (ACTBM) may predict decreased blood cells nadirs in anal cancer patients undergoing concurrent chemo-radiation. Methods: Forty-four patients were analyzed and pelvic active bone marrow (ACTBM) was characterized employing 18FDG-PET. Dosimetric parameters on dose–volume histograms were correlated to nadirs with generalized linear modeling. Results: ACTBM mean dose was significantly correlated to white blood cell (β = −1.338; 95%CI: −2.455/−0.221; p = 0.020), absolute neutrophil count (β = −1.651; 95%CI: −3.284/−0.183; p = 0.048), and platelets (β = −0.031; 95%CI: −0.057/−0.004; p = 0.024) nadirs. Other dosimetric parameters were found to be correlated (ACTBM-V10,-V20,-V30and-V40). Conclusions: 18FDG-PET is able to define active bone marrow and may predict for decreased blood cells count nadirs.

Original languageEnglish
Pages (from-to)279-288
Number of pages10
JournalCancer Investigation
Volume36
Issue number5
DOIs
Publication statusPublished - 28 May 2018
Externally publishedYes

Keywords

  • Anal cancer
  • Bone marrow
  • Concomitant radiochemotherapy
  • Hematologic toxicity
  • IMRT
  • PET
  • Radiotherapy

Fingerprint

Dive into the research topics of 'Dose to Pelvic Bone Marrow Defined with FDG-PET Predicts for Hematologic Nadirs in Anal Cancer Patients Treated with Concurrent Chemo-radiation'. Together they form a unique fingerprint.

Cite this